1. Introduction {#s0005}
===============

The coronavirus disease 2019 (COVID-19) pandemic, as declared by the World Health Organization on 11 March 2020 \[[@bb0005]\], has accumulated 6057.853 confirmed cases globally until June 1 \[[@bb0010]\]. The etiologic agent of COVID-19 is a novel beta coronavirus \[[@bb0015]\], which was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses \[[@bb0020]\]. Zhou et al. established that the SARS-CoV-2 is 96% identical at the whole-genome level to a bat SARS-like coronavirus and 79.5% identical to SARS-CoV \[[@bb0025]\].

Coronaviruses possess an enveloped, single, positive-stranded RNA genome that encodes for four membrane polypeptides, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins \[[@bb0030]\]. The spike glycoprotein (S) present in the coronavirus envelope is used to bind and penetrate the host cells. The S protein is composed of two subunits: S1 and S2; the S1 subunit allows the virus to bind the host cell receptors, while S2 enables the fusion of viral and cellular membranes. The SARS-CoV-2 entry into target cells requires S protein priming by cellular proteases, which entails S protein cleavage at the S1/S2 and S2\' sites \[[@bb0035]\]. Depending on virus strains and cell types, coronavirus (CoV) S proteins may be cleaved by one or several host proteases, including furin, cathepsins, transmembrane protease serine protease-2 (TMPRSS-2), neutrophil elastase (ELANE), and probably TMPRSS11A \[[@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075]\]. The availability of these proteases on target cells largely determines whether CoV particles enter cells through plasma membrane or endocytosis. Hoffmann et al. demonstrated that SARS-CoV-2 uses the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) for entry into target cells and the transmembrane protease 2 (TMPRSS2) for S protein priming \[[@bb0080]\]. In the same way, Ou et al. found that cathepsin L (CTSL) is critical for virus entry \[[@bb0085]\]. It has also been reported that the S protein of the A2a subtype has an additional elastase-specific proteolytic cleavage site that endows the virus with an increased ability to penetrate host cells \[[@bb0050]\]. This virus subtype was reported in China and spread rapidly in Europe and North America \[[@bb0090],[@bb0095]\].

ACE2 is a carboxypeptidase that converts angiotensin II to angiotensin-(1-7) \[Ang-(1-7)\], which evokes anti-fibrosis, anti-hypertrophy, vasodilatation, and other beneficial effects \[[@bb0100], [@bb0105], [@bb0110]\]. Tissue-bound or membrane-bound ACE2 is a kind of transmembrane protein with a single metalloprotease active site and a transmembrane domain \[[@bb0115],[@bb0120]\]. The ACE2 receptor is expressed at high levels not only in alveolar type-2 cells in the lung, but also in liver cholangiocytes, myocardial cells, esophagus keratinocytes, kidney proximal tubules, bladder urothelial cells, and gastrointestinal epithelial cells \[[@bb0125],[@bb0130]\]. In the lung, ACE2 is abundantly expressed in Clara cells, type I and II alveolar epithelial cells, macrophages, endothelium, vascular smooth muscle cells, and bronchial epithelia \[[@bb0135]\]. ACE2 is encoded in the chromosome Xp22 and spans 39.98 kb of genomic DNA. This gene generates two transcripts that originate the same 805-amino-acid-residue protein; one transcript consists of 18 exons and 17 introns (transcript length: 3339 bps) and the other is composed of 19 exons and 18 introns (transcript length: 3507 bps). The *ACE2* gene exhibits a high level of polymorphism; in fact, some single nucleotide polymorphisms (SNPs) have been associated with susceptibility to diseases, such as type 2 diabetes and hypertension \[[@bb0140],[@bb0145]\].

The transmembrane serine protease TMPRSS2 is an essential enzyme that can cleave hemagglutinin of many subtypes of the influenza virus and the coronavirus S protein \[[@bb0150],[@bb0155]\]. It has been reported that TMPRSS2 deficiency protects mice against H1N1, mouse-adapted H1N1, and H7N9 influenza A virus infections \[[@bb0150],[@bb0160]\]. Recently, it has been shown that TMPRSS2 can help SARS-CoV-2 enter host cells by cleaving the S protein \[[@bb0080]\]. Matsuyama et al. demonstrated that TMPRSS2-expressing cell lines are highly susceptible to SARS-CoV, MERS-CoV, and SARS-CoV-2 \[[@bb0165]\]. The gene that encodes TMPRSS2 is polymorphic and is considered a susceptibility gene for H1N1 and H7N9 influenza \[[@bb0170]\]. Similarly, TMPRSS11A is another member of the subfamily of type II transmembrane serine proteases. This enzyme is synthesized as a zymogen and can be activated upon auto-proteolytic cleavage at a site located between the protease domain and the stem region \[[@bb0175]\]. Zmora et al. demonstrated that TMPRSS11A cleaves and activates the MERS-CoV spike protein and the influenza A virus hemagglutinin \[[@bb0180]\].

Elastase is known to be secreted by neutrophils as part of an inflammatory response to a viral infection and is also produced by opportunistic bacteria that can colonize virally infected respiratory tissue \[[@bb0185]\]. The increase of elastase activity as a result of an extreme inflammatory process produces an important pulmonary injury contributing significantly to the pathogenesis of chronic obstructive pulmonary disease, cystic fibrosis, acute respiratory distress syndrome, and pulmonary fibrosis \[[@bb0190],[@bb0195]\].

Cathepsin L is a peptidase that preferentially cleaves peptide bonds with aromatic residues in the P2 position and hydrophobic residues in the P3 position \[[@bb0200]\]. It has been previously reported that cathepsin L participates in the viral glycoprotein processing of Ebola and SARS-CoV. It is well established that this viral process is important for cell membrane fusion and host cell entry \[[@bb0205]\]. Using inhibitors of cathepsin B and L in HEK 293/hACE2 cells, Ou et al. \[[@bb0085]\] demonstrated that the treatment with cathepsin L inhibitor decreases the entry of SARS-CoV-2 into the cells. This result suggests that cathepsin L could be very important for S protein priming in lysosome for viral entry.

The outbreak of the COVID-19 pandemic shows marked geographic variation in its prevalence and mortality. This variability could be due to both the presence of several subtypes of the virus and the genetic differences in the human populations \[[@bb0090],[@bb0095],[@bb0210], [@bb0215], [@bb0220]\]. Considering this fact and the important role of the ACE2, TMPRSS2, TMPRSS11A, cathepsin L, and elastase in the process of virus entry into the host cell, the present study aims to propose possible variants in these *loci* for genetic association studies in patients with SARS-CoV-2 infection.

2. Methods {#s0010}
==========

To identify the different single nucleotide variants (or insertions/deletions; INDELs) and their allelic frequencies, *ACE2* (ID 59272), *TMPRSS2* (ID 7113, protein sequence: NP_005647.3), *TMPRSS11A* (ID 339967, protein sequence; NP_001107859.1), *ELANE* (ID 1991, protein sequence: NP 001963.1)), and *CTSL* (ID 1514) SNPs were retrieved from dbSNPs (GRCh38), Ensembl Genome Browser, and 1000 Genome Project (phase 3). The number and origin of the subjects that comprise the four populations included in our analysis are as follows: (a) Mexican individuals (Americans) from Los Angeles: 50, 64, and 67 samples reported in dbSNPs, Ensembl Genome Browser, and 1000 Genome Project, respectively; (b) Han Chinese from Beijing (Asians): 43, 103, and 103 samples reported in dbSNPs, Ensembl Genome Browser, and 1000 Genome Project, respectively; (c) Yoruba from Ibadan, Nigeria (Africans): 113, 109, and 108 samples reported in dbSNPs, Ensembl Genome Browser, and 1000 Genome Project, respectively; (d) British (Europeans): 91 and 92 samples reported in Ensembl Genome Browser and 1000 Genome Project, respectively. All genes were identified by their ID and we took 2000 bp upstream of the transcription start site as the promoter region. The exons were divided into 5′ UTR and 3′ UTR regions, and the coding sequence. As for our in silico analysis, we used web-based tools (i) to identify the potential functional impact of the variants included in the tables, (ii) to test for linkage disequilibrium (LD), and (iii) to determine if these variants were tagSNPs among them. The SNPs function prediction of the SNPinfo Web Server (<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html>) was used for the in silico analysis; this web-based tool identifies whether alleles create binding sites for microRNAs, for transcription factors or proteins that regulate splicing. In addition, SNPinfo predicts the effect of nonsynonymous and synonymous alleles on protein function. We conducted a prediction of deleterious SNPs (with a minor allele frequency greater than 1.5% in any of the four populations included in our study) using Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and SIFT (<https://sift.bii.a-star.edu.sg/>). These web-based tools predict a possible impact of non-synonymous substitutions on the protein structure and function. Additionally, we used the ModPred server, which is a sequence-based predictor of potential post-transcriptional modification sites in proteins (<http://montana.informatics.indiana.edu/ModPred/index.html>). Of note, we used both sequence and structure-based prediction tools of proteins. After sequence alignment, we identified the potential deleterious effect of alleles of non-synonymous SNPs in *TMPRSS2*, *TMPRSS11A*, and *ELANE*. Linkage disequilibrium (LD) among SNPs included in our analysis is described at the bottom of each table. Several polymorphisms are TagSNPs because they are either in strong LD or have an r^2^ \>0.95. Hence, it is enough to analyze a single TagSNP to capture other SNPs (because of the high LD between them), which are potentially associated with COVID-19.

Genotype information of *ACE2*, *TMPRSS2*, *TMPRSS11A*, *ELANE*, and *CTSL* SNPs was downloaded from the Ensembl Genome Browser (<https://www.ensembl.org/index.html>). To obtain the LD between the SNPs of the 5 genes, we used the Haploview (V. 4.2) program (<https://www.broadinstitute.org/haploview/downloads>).

3. Results {#s0015}
==========

Among all the genes analyzed, we included polymorphisms with frequencies greater than 1.5% in at least one of the four populations from the American, African, European, and Asian continents.

3.1. ACE2 polymorphisms {#s0020}
-----------------------

[Table 1](#t0005){ref-type="table"} shows thirteen *ACE2* polymorphisms with a frequency greater than 1.5% in at least one of the populations reviewed. As can be seen, two of these polymorphisms (rs35803318 and rs4646179) were located in the coding sequence without a change of amino acid. On the other hand, three SNPs (located in the promoter or in the 5′ region near the gene) had a possible functional effect: rs7885856 (both alleles can create binding sites for AP2alpha, BCL6, CEBP, and ETS transcription factors), rs9698134 (the *C* allele can produce a binding site for HIC1 transcription factor), and rs9698150 (both alleles produced binding sites for BRCA, DBP, ETF, MYB, RFX, and WT1).Table 1*ACE2* polymorphisms.Table 1*ACE2*MAF (%) in populations with different ancestryPotential functional effectVariant IDMinor alleleAMER (MXL)AFR (YRI)EUR (GBR)EAS (CHB)Amino acid position and changeYNCoding sequencers35803318*C*/*TT*8.304.40Val749ValXrs4646179*A*/*GG*012.200Asn690AsnX  Promoter and 5′ near the geners113009615*AAAAAA*/*AAAAAAA* (INDEL)*A*2.117.70.70Xrs7885856*G*/*AA*2.1[a](#tf0005){ref-type="table-fn"}7.300Both alleles can create binding sites for AP2ALPHA, BCL6, CEBP, and ETS.rs112621533*T*/*CC*08.50.7[c](#tf0015){ref-type="table-fn"}0Xrs11336754*ATTT*/*ATT* (INDEL)*ATT*4.214.60.72.5Xrs760084155*G*/*AA*18.7000Xrs765471058*A*/*TT*17.7000Xrs9698134*C*/*TT*2.1[a](#tf0005){ref-type="table-fn"}17.7[b](#tf0010){ref-type="table-fn"}0.7[c](#tf0015){ref-type="table-fn"}0Allele C can create a binding site for HIC1rs9698150*G*/*CC*2.1[a](#tf0005){ref-type="table-fn"}17.7[b](#tf0010){ref-type="table-fn"}0.7[c](#tf0015){ref-type="table-fn"}0Both alleles can create binding sites for BRCA, DBP, ETF, MYB, RFX, and WT1rs112593415*A*/*GG*2.1[a](#tf0005){ref-type="table-fn"}17.7[b](#tf0010){ref-type="table-fn"}0.7[c](#tf0015){ref-type="table-fn"}0Xrs184697926*A*/*CC*00011.9Xrs142049267*A*/*GG*04.300X[^1][^2][^3][^4][^5]

3.2. TMPRSS2 polymorphisms {#s0025}
--------------------------

The *TMPRSS2* polymorphisms are shown in [Table 2](#t0010){ref-type="table"} . In this case, thirty-nine polymorphisms had a frequency higher than 1.5% in at least one of the populations; four of them were located in the coding sequence and only one (rs12329760) produces an amino acid change (Val160Met). This change was probably damaging (PolyPhen-2, score 0.989, sensitivity 0.72, specificity 0.97). Indeed, using SIFT, we identified that this variant was deleterious (SIFT score 0.009). Our analysis, based in the ModPred server, showed that neither Val160 nor 160Met undergoes any possible post-translational modification (e.g., acetylation, proteolytic cleavage, glycosylation, phosphorylation). As for this gene, seventeen polymorphisms located in the promoter, in the 5′ region near the gene, and the 3′ UTR region had a possible functional effect. Ten polymorphisms located in the promoter and the 5′ region near the gene produced binding sites for several transcription factors, whereas seven located in the 3′ UTR region created potential binding sites for several microRNAs.Table 2*TMPRSS2* polymorphisms.Table 2*TMPRSS2*MAF (%) in populations with different ancestryPotential functional effectVariant IDMinor alleleAMER (MXL)AFR (YRI)EUR (GBR)EAS (CHB)Amino acid position and changeYNCoding sequencers61735794*C*/*TT*0.802.80Gly385GlyXrs2298659*G*/*AA*31.216.221.429.6Gly290GlyXrs17854725*A*/*GG*47.736.156.417.5Ile256IleXrs61735789*G*/*AA*1.600.50Tyr180TyrXrs12329760*C*/*TT*18.025.520.941.3Val160MetProbably Damaging (by PolyPhen-2)\
Deleterious (by SIFT)\
Without post-translational modification (by ModPred server)rs3787950*T*/*CC*1.630.17.111.7Thr75ThrXrs61735792*G*/*AA*001.10Pro63ProX  Promoter and 5′ near the geners4303794*A*/*CC*28.1\*41.2^¤¤^41.8^‡^1^±^The *C* allele creates binding sites for AP2, and SP1, and WT1rs11088551*A*/*GG*28.1\*41.2^¤¤^41.8^‡^1^±^The *A* allele creates inding sites for BRCA, MYB, NF1, and RFXrs66492316*GGCGCAGCGC*/*C* (INDEL)*C*28.141.2^¤¤^41.81Xrs4303795*A*/*GG*28.1\*41.241.2^‡^1^±^The *G* allele creates binding sites for HNF4 and KID3rs5844077*G*/*GA* (INDEL)*G*29.625.325.88.3Xrs76833541*G*/*AA*31.3010.40Xrs4283504*G*/*TT*16.437.012.623.3The *T* allele creates binding sites for DBP, HSF1, and NKX25rs12481984*T*/*CC*27.3\*39.4^¤^40.7^‡^1^±^The *C* allele creates a binding site for HAND1E47rs28707508*G*/*AA*25.8\*38.4^¤^40.1^‡^1^±^The *A* allele creates binding sites for HNF3, ALPHA, and TBPrs552257429*C*/*CT* (INDEL)*CT*26.638.439.01.5Xrs12626358*C*/*GG*26.826.49.356.8The *G* allele creates a binding site for KAISOrs8128074*C*/*TT*16.42.812.623.8The *C* allele creates binding sites for ETF, KROX, LRF, and SPZ1rs56218846*G*/*AA*25.8\*40.3^¤^40.1^‡^1The *A* allele creates a binding site for PPAR_DR1rs11281229*T*/*TCCAGG* (INDEL)*TCCAGG*25.840.340.10.9Xrs8127674*A*/*GG*25.8\*40.3^¤^40.1^‡^1The *G* allele creates binding sites for AP2ALPHA, ETF, and SPZ1  3′ near the geners11088550*G*/*AA*12.5\*\*09.30Xrs463727*T*/*AA*26.64.246.20.5Xrs462471*G*/*AA*36.7\*\*\*34.3^¤¤¤^13.7^‡‡^53.4^±±^Xrs76000363*G*/*AA*12.5\*\*5.612.1^‡‡^6.3\*\*X  3′ UTRrs143680939*GA*/*G* (INDEL)*G*12.55.612.16.8Xrs456142*C*/*TT*36.7\*\*\*34.3^¤¤¤^13.7^‡‡^53.4^±±^The *C* allele creates a binding site for hsa-miR-548c-3prs112657409*C*/*TT*0.87.906.3^±±±±^Xrs2838038*A*/*TT*12.5\*\*4.612.1^‡‡^6.3^±±±^The *T* allele can create a binding site for hsa-miR-943rs462574*G*/*AA*24.214.8^¤¤¤¤^1.747.1^±±^The *A* allele can create a binding site for hsa-miR-1324rs456298*A*/*TT*37.5\*\*\*34.3^¤¤¤^13.7^‡‡^53.4^±±^The *A* allele can create a binding site for hsa-miR-450b-5prs17001042*G*/*AA*0.813.900The *A* alleles can create a binding site for hsa-miR-220brs11910678*T*/*CC*1.613.9^¤¤¤¤^06.3^±±±±^Xrs77675406*G*/*AA*12.5\*\*4.612.1^‡‡^6.3^±±±^Xrs12627374*C*/*TT*00013.6The *C* allele can create a binding site for hsa-miR-345rs62217525*C*/*TT*3.906.00The *C* allele can create a binding site for hsa-miR-1226rs77996454*G*/*AA*4.60.800Xrs149695119*TG*/*T* (DELETION)*T*22.70.800X  Among *MX1* and *TMPRSS2*rs35074065*AC*/*A* (INDEL)*A* or del*C*26.64.643.40.5It has been reported that del*C* affects the TMPRSS2 and MX1 expressionRef [@bb0050][^6][^7][^8][^9]

3.3. TMPRSS11A polymorphisms {#s0030}
----------------------------

Out of twenty polymorphisms in the *TMPRSS11A* gene, six were in the coding sequence; three of these generated a nonsynonymous substitution (rs353163-Arg290Gln, rs139010197-Lys48Arg, rs977728-Met1Ile). According to PolyPhen-2 results, rs353163 was possibly benign (Polyphen-2 score 0.015, sensitivity 0.96, specificity 0.79) and tolerated (SIFT score 1). Using ModPred, we found that 290Gln was not affected; in contrast, variant Arg290 was predicted to undergo a translational modification: a proteolytic cleavage (score 0.71 and medium confidence). A similar result was observed with the 48Arg variant (rs139010197); this variant was predicted to be benign (PolyPhen-2 score 0.02, sensitive 0.95, specificity 0.8) and tolerated (SIFT score 0.53). Using ModPred, we identified that the 48Arg variant might undergo a proteolytic cleavage (score 0.57, low confidence). Alternatively, we did not identify any effect of Met1 or 1IIe (rs977728). Both five polymorphisms located in the promoter and the 5′ region near the gene and the two located in the 5′UTR region had a possible functional effect; these SNPs produced binding sites for several transcription factors. Finally, three out of five polymorphisms located in the 3′-UTR region created binding sites for some microRNAs ([Table 3](#t0015){ref-type="table"} ).Table 3*TMPRSS11A* polymorphisms.Table 3*TMPRSS11A*MAF (%) in populations with different ancestryPotential functional effectVariant IDMinor alleleAMER (MXL)AFR (YRI)EUR (GBR)EAS (CHB)Amino acid position and changeYNCoding sequencers1371932*A*/*GG*46.132.449.531.1^±^Asp334AspXrs353163*C*/*TT*46.113.440.115.5Arg290GlnBenign (by PolyPhen-2)\
Tolerated (by SIFT)\
Arg290 originates a proteolytic cleavage (by ModPred server)rs1370840*G*/*AA*41.4\*55.620.3^‡^10.7^±±^Thr81ThrXrs139010197*T*/*CC*0.804.40Lys48ArgBenign (by PolyPhen-2)\
Tolerated (by SIFT)\
48Arg originates a proteolytic cleavage (by ModPred server)rs11930532*T*/*CC*41.4\*78.720.3^‡^10.7^±±^Val6ValXrs977728*C*/*TT*39.1\*10.620.9^‡^9.7^±±^Met1IleBenign (by PolyPhen-2)\
Tolerated (by SIFT)\
Without post-translational modification (by ModPred server)  Promoter and 5′ near the geners17088849*T*/*CC*15.613.422.053.4The *C* allele creates binding sites for BRCA and MYBrs200058897*TA*/*T* (INDEL)*T*5.513.95.00Xrs536791104*C*/*GG*5.5\*\*13.9¤5.0^‡‡^0Xrs6552135*A*/*GG*37.50.552.236.9The *C* allele creates binding sites for CEBPA, CEBPDELTA, and CEBPrs17088850*A*/*GG*5.5\*\*20.45.0^‡‡^0The *C* allele creates binding sites for BRCA and MYBrs17088851*T*/*CC*5.5\*\*11.6¤5.0^‡‡^0The *C* allele creates binding sites for AREB6, ETF, KID3, and SPZ1rs720009*T*/*AA*1.624.100The *C* allele creates a binding site for GATA6  5′ UTRrs6552134*A*/*GG*46.979.225.89.7^±±^The *G* allele creates a binding site for AP2ALPHArs11947613*G*/*AA*2.347.700The *G* allele creates a binding site for TBP  3′ UTRrs4860265*A*/*GG*47.737.434.130.1^±^The *G* allele creates a binding site for hsa-miR-658rs9998258*T*/*CC*2.3\*\*\*1.86.6^‡‡‡^0The *T* allele creates binding sites for hsa-miR-1, hsa-miR-613, and hsa-miR-148brs33929303*C*/*TT*20.325.931.39.2Xrs28648375*T*/*AA*2.3\*\*\*06.6^‡‡‡^0The *T* allele creates a binding site for hsa-miR-1244rs12646286*C*/*TT*25.85.118.160.7X[^10][^11][^12][^13]

3.4. ELANE polymorphism {#s0035}
-----------------------

The polymorphisms of the *ELANE* gene are shown in [Table 4](#t0020){ref-type="table"} . As can be seen, two of them (rs17223045 and rs17216663) were located in the coding region. In fact, according to the bioinformatic analysis, rs17216663 provoked a change of amino acid (Pro257Leu), which is benign (PolyPhen-2 score 0.01, sensitivity 0.96, specificity 0.77) and tolerated (SIFT score 0.197). Using ModPred, we found that Pro257 undergoes hydroxylation (score 0.80, medium confidence), while 257Leu is not predicted to be post-translationally modified. In this gene, 12 polymorphisms had a possible functional effect. These polymorphisms were located in several regions of the gene and spawned binding sites for some transcription factors.Table 4*ELANE* polymorphisms.Table 4*ELANE*MAF (%) in populations with different ancestryPotential functional effectVariant IDMinor alleleAMER (MXL)AFR (YRI)EUR (GBR)EAS (CHB)Amino acid position and changeYNCoding sequencers17223045*C*/*TT*0.811.61.10Asn130AsnXrs17216663*C*/*TT*1.600.60Pro257LeuBenign (by PolyPhen-2)\
Tolerated (by SIFT)\
Pro257 undergoes a hydroxylation (by ModPred server)  Promoter and 5′ near the geners74876755*C*/*TT*05.600Xrs10413889*G*/*AA*4.718.112.60.5The *A* allele creates a binding site for SPZ1rs3761007*G*/*AA*4.707.725.7The *G* allele creates a binding site for DR4rs3761006*G*/*AA*5.500.518.0The *A* allele creates binding sites for OCT and P53rs10409474*C*/*GG*10.228.212.628.6The *G* allele creates a binding site for YY1rs3761005*T*/*AA*44.568.531.359.7The *A* allele creates binding sites for CEBPDELTA and YY1rs351107*T*/*GG*0.89.31.70The *G* allele creates a binding site for DBPrs3761001*G*/*AA*14.856.025.3\*29.6^‡^The *G* allele creates binding sites for USF and LRFrs2007647*G*/*AA*7.09.724.2\*1.0The *A* allele creates binding sites for ETS, HMGIY, NFAT, and OCT1rs17216593*C*/*TT*0.87.40.60The *T* allele creates binding sites for PAX8 and SREBPrs740021*C*/*AA*7.027.31.128.2^‡^The *A* allele creates a binding site for CEBPGAMMA  3′ near the geners187713106*T*/*AA*0.811.13.30Xrs113311784*T*/*TA* (INDEL)*TA*12.56.516.538.8Xrs6510983*C*/*TT*15.638.025.81.9The *A* allele creates a binding site for CEBPArs17223066*G*/*AA*54.723.144.533.5The *G* allele creates a binding site for CREB[^14][^15][^16]

3.5. CTSL polymorphisms {#s0040}
-----------------------

In this gene, one polymorphism (rs11541204) was in the coding region, without a change of amino acid. Four out of nine polymorphisms located in the promoter region and the 5′ region near the gene, presented a possible functional effect: a binding site for some transcription factors. Both the polymorphism located in the 5′ UTR region and the one located in the 3′ region near the gene generated binding sites for transcriptional factors ([Table 5](#t0025){ref-type="table"} ).Table 5*Cathepsin* L polymorphisms.Table 5*CTSL* (*Cathepsin* L)MAF (%) in populations with different ancestryPotential functional effectVariant IDMinor alleleAMER (MXL)AFR (YRI)EUR (GBR)EAS (CHB)Amino acid position and changeYNCoding sequencers11541204*G*/*AA*005.00Gln134GlnX  Promoter and 5′ near the geners78985072*G*/*AA*4.7\*0015.5^±^Xrs142421833*C*/*TT*4.7\*0015.5^±^Xrs3128509*G*/*AA*45.313.041.83.4Both alleles can create binding sites for BRCA, GATA4, MYB, and RFXrs111786311*T*/*GG*1.616.22.8^‡^0Xrs11389221*C*/*CAAA* (INDEL)*CAAA*43.815.351.776.7Xrs56952354*A*/*TT*2.34.600Both alleles can create binding sites for GATA, GFI1, and TEL2rs75567776*G*/*CC*2.37.900Xrs3118869*C*/*AA*39.846.847.332.5The *C* allele creates binding sites for SREBP, AHR, and AHRHIFrs41307457*C*/*AA*3.123.62.8^‡^0Both alleles can create binding sites for BRCA, DBP, LRF, MYB, and STAT4  5′ UTRrs41312184*C*/*TT*1.60.511.00Both alleles can create binding sites for STAT, and RFX. The C allele can create a binding site for SF2ASF1  3′ near the geners59063901*G*/*AA*0.83.72.8^‡^0Both alleles can create binding sites for STAT, SPZ1, and GABP[^17][^18][^19]

3.6. LD between SNPs of ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL {#s0045}
-----------------------------------------------------------------

We conducted an LD analysis between the SNPs in *ACE2* ([Fig. 1](#f0005){ref-type="fig"} ), *TMPRSS2* ([Fig. 2](#f0010){ref-type="fig"} ), *TMPRSS11A* ([Fig. 3](#f0015){ref-type="fig"} ), *ELANE* ([Fig. 4](#f0020){ref-type="fig"} ), and *CTSL* ([Fig. 5](#f0025){ref-type="fig"} ) proposed here. Thus, our analysis of LD included SNPs in these 5 genes but not INDELs. We observed several non-informative SNPs (minor allele frequency = 0%) in the 4 populations included in our analysis. For example, for *TMPRSS2*, 2, 7, 5, and 8 SNPs were eliminated in the American, African, European, and Asian populations included in our study, respectively. This reflects the heterogeneity between the populations. Similar results can be observed for *ACE2*, *TMPRSS11A*, *ELANE*, and *CTSL*.Fig. 1Linkage disequilibrium (r^2^) in the *ACE2* gene in the included populations. Of the 13 variants shown in [Table 1](#t0005){ref-type="table"}, two were INDELs and in two of them no information was found, so they were not added to the Haploview program. Of the remaining 9, some were not polymorphic in the different populations. Linkage disequilibrium (LD) between variants is shown in the figures, 5 in Americans ([Fig. 1](#f0005){ref-type="fig"}A), 7 in Africans ([Fig. 1](#f0005){ref-type="fig"}B), 5 in Europeans ([Fig. 1](#f0005){ref-type="fig"}C). In Asians, none of the variants were in LD.Fig. 1Fig. 2Linkage disequilibrium (r^2^) in the *TMPRSS2* gene in the included populations. Of the 39 variants shown in [Table 2](#t0010){ref-type="table"}, five were INDELs and one a deletion, so they were not added to the Haploview program. Of the remaining 33, some were not polymorphic in the different populations. Linkage disequilibrium between variants is shown in the figures, 31 in Americans ([Fig. 2](#f0010){ref-type="fig"}A), 26 in Africans ([Fig. 2](#f0010){ref-type="fig"}B), 28 in Europeans ([Fig. 2](#f0010){ref-type="fig"}C), and 24 in Asians ([Fig. 2](#f0010){ref-type="fig"}D).Fig. 2Fig. 3Linkage disequilibrium (r^2^) in the *TMPRSS11A* gene in the included populations. Of the 20 variants shown in [Table 3](#t0015){ref-type="table"}, one was INDEL and was not added to the Haploview program. Of the remaining 19, some were not polymorphic in the different populations. Linkage disequilibrium between variants is shown in the figures, 19 in Americans ([Fig. 3](#f0015){ref-type="fig"}A), 17 in Africans ([Fig. 3](#f0015){ref-type="fig"}B), 17 in Europeans ([Fig. 3](#f0015){ref-type="fig"}C), and 11 in Asians ([Fig. 3](#f0015){ref-type="fig"}D).Fig. 3Fig. 4Linkage disequilibrium (r^2^) in the *ELANE* gene in the included populations. Of the 17 variants shown in [Table 4](#t0020){ref-type="table"}, one was INDEL and was not added to the Haploview program. Of the remaining 16, some were not polymorphic in the different populations. Linkage disequilibrium between variants is shown in the figures, 15 in Americans ([Fig. 4](#f0020){ref-type="fig"}A), 13 in Africans ([Fig. 4](#f0020){ref-type="fig"}B), 15 in Europeans ([Fig. 4](#f0020){ref-type="fig"}C), and 10 in Asians ([Fig. 4](#f0020){ref-type="fig"}D).Fig. 4Fig. 5Linkage disequilibrium (r^2^) in the *CTSL* gene in the included populations. Of the 12 variants shown in [Table 5](#t0025){ref-type="table"}, one was INDEL and was not added to the Haploview program. Of the remaining 11, some were not polymorphic in the different populations. Linkage disequilibrium between variants is shown in the figures, 10 in Americans ([Fig. 5](#f0025){ref-type="fig"}A), 8 in Africans ([Fig. 5](#f0025){ref-type="fig"}B), 7 in Europeans ([Fig. 5](#f0025){ref-type="fig"}C), and 4 in Asians ([Fig. 5](#f0025){ref-type="fig"}D).Fig. 5

4. Discussion {#s0050}
=============

Using the information about allelic frequencies obtained from dbSNPs, Ensembl Genome Browser, and the 1000 Genome Project, as well as different wed-based tools, we defined some polymorphic variants in the *ACE2*, *TMPRSS2*, *TMPRSS11A*, *ELANE*, and *CTSL* genes that could be important for association studies in the SARS-CoV-2 infection. SARS-Cov-2 enters the cell by binding its S protein with cellular receptors (e.g., ACE2 membrane-bound protein) \[[@bb0080]\]. Some proteases, such as TMPRSS2, cathepsin L, neutrophil elastase, and probably TMPRSS11A participate in this process \[[@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075]\]; in fact, polymorphisms in their encoding genes could not only have an impact in the expression and/or structure of these proteases but also be associated with SARS-CoV-2 infection susceptibility.

Even though most of the *ACE2* variants occur at low frequencies in human populations, we detected three polymorphisms with a possible functional effect: binding site generation for some transcription factors. AP2alpha, BCL6, CEBP, ETS (rs7885856), HIC1 (rs9698134), BRCA, DBP, ETF, MYB, RFX, and WT1 (rs9698150) are some of these factors, which could have a role in the virus infection. It has been reported that BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection \[[@bb0225]\]. Han et al. \[[@bb0230]\] demonstrated that the CEBP alpha participates in the activation of hfg12 prothrombinase during SARS-CoV infection, thus having an important role in the development of thrombosis in SARS. The three *ACE2* polymorphisms with possible functional effects have a high frequency of its minor allele only in the African population. Thus, these polymorphisms could be genetic targets for association studies in this population. Two recent studies have analyzed the association of *ACE2* polymorphisms with susceptibility to SARS-CoV-2 infection \[[@bb0210],[@bb0215]\]; however, the evidence stating that low-frequency variants can participate in SARS-CoV-2 infection is not convincing. In the same way, Cao et al. \[[@bb0235]\] systematically investigated the candidate functional-coding variants in *ACE2* and the allele frequency differences between several populations. The results of this analysis suggested that there are no variants in the *ACE2* gene resistant to coronavirus S-protein binding in the study populations.

It was recently suggested that a renin-angiotensin system (RAS) imbalance impacts all stages of SARS-CoV-2 infection and clinical findings thereof, placing RAS molecules at the center of COVID-19 pathophysiology. The imbalance between the ACE/Ang II/AT1R and ACE2/Ang-(1-7)/MasR axes results in multiple organ dysfunction and uncontrolled inflammatory response \[[@bb0240]\]. The insertion/deletion (*I*/*D*) polymorphism of the *ACE1* gene is associated with plasma and tissue levels of ACE. In this context, Delanghe et al. \[[@bb0245]\] analyzed not only the prevalence and mortality data (per 1,000,000 inhabitants) of the COVID-19 infection of several countries but also the frequency of several polymorphisms in genes of some human plasma proteins, including the *ACE I*/*D* polymorphism. The results of this study suggest that the prevalence of COVID-19 is significantly correlated with the *ACE1* polymorphism.

Contrary to the *ACE2* gene, the polymorphisms in the *TMPRSS2* gene had a considerable variation in its frequencies between human populations. In this gene, we detected one polymorphism (rs12329760) located in the coding sequence that created a nonsynonymous substitution (Val160Met). Our in silico analysis using ModPred did not show a possible effect of the *TMPRSS2* rs12329760 polymorphism on any post-translational modification (e.g., proteolytic cleavage, acetylation, glycosylation, phosphorylation, and sulfation). However, this variant was predicted to be damaging by PolyPhen-2 and deleterious by SIFT. It has been recently reported that the *TMPRSS2* Val160Met variant decreases the stability of the protein, which might impede viral entry \[[@bb0250]\]. In a previous in silico analysis of the *TMPRSS2* gene, it was found that this polymorphism creates a de novo pocket protein \[[@bb0220]\]. The frequency of the minor allele of this polymorphism was high in the four study populations. Seventeen *TMPRSS2* polymorphisms (located in the promoter, in the 5′ region near the gene, and the 3′ UTR region) generated a possible functional effect: the binding of different transcription factors and microRNAs. Two of them had a high frequency of its minor allele in the four populations (rs4283504 and rs12626358) and created binding sites for the DBP, HSF1, NKX25, and KAISO factors. It has been reported that heat shock factor 1 (HSF1) is an innate repressor of HIV-induced inflammation \[[@bb0255]\]. The frequency of the minor allele of 7 of these polymorphisms was high in populations from the American, African, and European continents. However, in the Asian population, only 3 (rs4283504, rs12626358, and rs8128074) out of the ten polymorphisms were observed with a minor allele frequency higher than 10%. In the same *TMPRSS2* gene, we detected 7 polymorphisms with a functional effect: all of them producing binding sites for microRNAs and two of them (rs456142 and rs456298) with high frequencies of its minor allele in the four study populations. The rs12627374 polymorphism produces a binding site for the microRNA-345. This polymorphism only was present in the Han Chinese population. Using computational analysis, we observed that it can affect a wide spectrum of microRNAs profile \[[@bb0220]\].

Although we identified that the three non-synonymous variants of *TMPRSS11A* are benign (according to PolyPhen-2) or tolerated (using SIFT), two of them (rs353163-Arg290Gln and rs13901019-Lys48Arg) possibly undergo a post-translational modification: proteolytic cleavage (according to ModPred server). Moreover, since this variant is located in the catalytic domain, it has been suggested that its activity is reduced because of the impact on the protein three-dimensional structure \[[@bb0260]\]. On the other hand, the rs353163 (Arg290Gln) polymorphism has been associated with the risk of esophageal squamous cell carcinoma (52). Therefore, it is possible that these variants could affect viral entry; however, future functional studies should be carried out to establish its role on SARS-CoV-2 susceptibility. The minor allele of the rs353163 polymorphism was present in a high frequency in the four study populations. Another 10 polymorphisms in this gene evoke a possible functional effect. Five located in the promoter and the 5′ region near the gene and two in the 5′ UTR region produced binding sites for several transcription factors. On the other hand, three polymorphisms located in the 3′ UTR region created microRNAs binding sites. Out of these polymorphisms, the minor alleles of only 3 (rs17088849, rs6552134, and rs4860265) were present in high frequencies in the four populations. The minor alleles of three (rs17088850, rs17088851, rs720009) out of ten *TMPRSS11A* gene polymorphisms with a possible functional effect were seen in a high frequency only in the African population. It could be interesting to study the association of these polymorphisms with SARS-CoV-2 infection in African populations to define if they are related to the low infection rate in the continent.

In the *ELANE* gene that encodes the neutrophil elastase, 12 polymorphisms with possible functional effects were detected: ten in the promoter and the 5′ region near the gene, and two in the 3′ region near the gene. These twelve polymorphisms produced binding sites for several transcription factors and microRNAs. The minor allele of four of these polymorphisms (rs10409474, rs3761005, rs3761001, rs17223066) was present in high frequency in the four populations. The minor allele of two polymorphisms (rs3761007 and rs3761006) had a high frequency only in the Han Chinese population. In a like manner, the minor allele frequency of rs2007647 was high only in the European (British) population. As for the SARS-CoV-2 infection, these polymorphisms could be relevant in the Asian and European populations. The nonsynonymous *ELANE* Pro257Leu (rs17216663) variant is predicted to be benign (PolyPhen-2) and tolerated (SIFT). Nevertheless, we found with the ModPred server that Pro257 may undergo hydrolyzation, which could affect the function of the ELANE protein. Previously, one study reported that Pro257Leu (located in the ELANE carboxyl terminus) is a risk factor for severe congenital neutropenia; however, the biological significance of this variant remains uncertain \[[@bb0265]\]. Therefore, future functional studies are essential to determine its effect.

In the *CTSL* gene, six polymorphisms with possible functional effects were detected. These polymorphisms were located in several regions of the gene and created binding sites for transcription factors. The minor allele of one of these polymorphisms (rs41307457) showed a high frequency only in the African population. Similarly, the minor allele of rs41312184 was present in high frequency only in the European population. The association of these polymorphisms with the SARS-CoV-2 infection should be analyzed in these populations.

It is important to note the high heterogeneity in the different populations, which is evident in the linkage disequilibrium analysis that we carried out. Different linkage disequilibrium patterns were observed for each gene in each population. The above requires an adequate selection of the SNPs to be studied in each of the populations.

Of note, we did not evaluate potentially important variants located in the gene introns. Admittedly, some of these variants could have a role in producing different mRNAs and protein isoforms on these 5 genes. Even though the synonymous variants (substitutions that do not lead to an amino acid change) seem to have no functional effect on proteins, some authors have published an effect on the structure and function of them \[[@bb0270],[@bb0275]\]. In our study, we included only information from the dbSNPs, Ensembl Genome Browser, and 1000 Genome Project databases. Discrete sequence databases of individuals infected with SARS-CoV2 were not analyzed. The phenotypic classification was not linked with the allelic patterns.

In summary, using web-based tools, we identified herein some polymorphisms in the genes that encode proteins related to the SARS-CoV-2 entry into the host cells that could be used for genetic association studies.
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[^1]: ACE2; Angiotensin I Converting Enzyme 2, MAF; Minor allele frequency, AMER; Americans, AFR; Africans, EUR; Europeans, EAS; East Asia, MXL; Mexicans from Los Angeles, YRI; Yoruba in Ibadan, Nigeria, CHB; Han Chinese in Beijing, China, GBR; British in England and Scotland, Y; Yes, N; No, INDEL; Insertion/Deletion, LD; Linkage disequilibrium. CCDS; consensus coding sequence.

[^2]: *ACE2* is located on chromosome Xp22.2. Five transcripts have been reported for ACE2, two of them synthesize the CCDS of 805 amino acids. The first transcript consists of 18 exons and 17 introns, 18 exons encode this protein, transcript length; 3339 bps. The second transcript consists of 19 exons and 18 introns, the CCDS consist of 18 exons, transcript length; 3507 bps.

[^3]: Variants in high LD or tagSNPs between them in an American population.

[^4]: Variants in high LD or tagSNPs between them in an African population.

[^5]: Variants in high LD or tagSNPs between them in a European population.

[^6]: \*, \* \*, \* \* \* Variants in high LD or tagSNPs between them in an American population. ^¤^, ^¤¤^,^¤¤¤^, ^¤¤¤¤^ Variants in high LD or tagSNPs between them in an African population.

[^7]: ^‡^, ^‡‡^, Variants in high LD or tagSNPs between them in a European population. ^±^, ^±±^, ^±±±^, ^±±±±^ Variants in high LD or tagSNPs between them in an Asian population.

[^8]: TMPRSS2; Transmembrane protease, serine 2, MAF; Minor allele frequency, AMER; Americans, AFR; Africans, EUR; Europeans, EAS; East Asia, MXL; Mexicans from Los Angeles, YRI; Yoruba in Ibadan, Nigeria, CHB; Han Chinese in Beijing, China, GBR; British in England and Scotland, Y; Yes, N; No, INDEL; Insertion/Deletion, UTR; Untranslated region, LD; Linkage disequilibrium, MX1; MX Dynamin Like GTPase 1. CCDS; Consensus coding sequence.

[^9]: *TMPRSS2* is located on chromosome 21q22.3.10 transcripts have been reported for TMPRSS2, six encode proteins, three of them are involved with CCDS. The first transcript consists of 14 exons and 13 introns, 13 exons encode this 492 amino-acid protein, transcript length; 3450 bps. The second transcript consists of 14 exons and 13 introns, 14 exons encode this 529 amino-acid protein, transcript length 3240 bp. The third transcript consists of 14 exons and 13 introns, 13 exons encode this 492 amino-acid protein, transcript length 1877 bps.

[^10]: \*, \* \*, \* \* \* Variants in high LD or tagSNPs between them in an American population. ¤, Variants in high LD or tagSNPs between them in an African population.

[^11]: ^‡^, ^‡‡^, ^‡‡‡^ Variants in high LD or tagSNPs between them in a European population. ^±^, ^±±^ Variants in high LD or tagSNPs between them in an Asian population.

[^12]: TMPRSS11A; Transmembrane Serine Protease 11A, MAF; Minor allele frequency, AMER; Americans, AFR; Africans, EUR; Europeans, EAS; East Asia, MXL; Mexicans from Los Angeles, YRI; Yoruba in Ibadan, Nigeria, CHB; Han Chinese in Beijing, China, GBR; British in England and Scotland, Y; Yes, N; No, INDEL; Insertion/Deletion, UTR; untranslated region, LD; Linkage disequilibrium. CCDS; consensus coding sequence.

[^13]: *TMPRSS11A* is located on chromosome 4q13.2. Three transcripts have been reported for TMPRSS11A, two produce CCDS. The first transcript consists of 10 exons and 9 introns, 10 exons encode this 421 amino-acid protein, transcript length; 3054 bps. The second transcript consists of 10 exons and 9 introns, 10 exons encode this 418 amino-acid protein, transcript length; 3247.

[^14]: \*, ^‡^, Variants in high LD or tagSNPs between them in a European, and Asian population, respectively.

[^15]: ELANE; Elastase, neutrophil expressed, MAF; Minor allele frequency, AMER; Americans, AFR; Africans, EUR; Europeans, EAS; East Asia, MXL; Mexicans from Los Angeles, YRI; Yoruba in Ibadan, Nigeria, CHB; Han Chinese in Beijing, China, GBR; British in England and Scotland, Y; Yes, N; No, INDEL; Insertion/Deletion, LD; Linkage disequilibrium. CCDS; consensus coding sequence.

[^16]: *ELANE* is located on chromosome 19p13.3. Two transcripts have been reported for this gene, which produce CCDS. The first transcript consists of 5 exons and 4 introns, 5 exons encode this 267 amino-acid protein, transcript length; 909 bps. The second transcript consists of 6 exons and 5 introns, 5 exons encode this 267 amino-acid protein, transcript length; 1028.

[^17]: \*, ^‡^, ^±^ Variants in high LD or are tagSNPs between them in an American, European, and Asian population, respectively.

[^18]: MAF; Minor allele frequency, AMER; American, AFR; Africans, EUR; Europeans, EAS; East Asia, MXL; Mexicans from Los Angeles, YRI; Yoruba in Ibadan, Nigeria, CHB; Han Chinese in Beijing, China, GBR; British in England and Scotland, Y; Yes, N; No, INDEL; Insertion/Deletion, UTR; untranslated region, LD; Linkage disequilibrium. CCDS; consensus coding sequence.

[^19]: *CTSL* is located on chromosome 9q21.33. Six transcripts have been reported for CTSL, three produce CCDS, and two of them synthesize the 333 amino acid protein. The first transcript consists of 8 exons and 7 introns, 7 exons encode this protein, transcript length; 1436 bps. The second transcript consists of 8 exons and 7 introns, 7 exons encode this protein, transcript length; 1654 pb.
